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ABSTRACT 
Purpose: To assess the ocular hypotensive effect  and tolerability   of fixed 
combination of brinzolamide 1%  and brimonidine  0.2%  in Indian patients with 
Open angle glaucoma 
Materials and methods: Newly diagnosed patients with  ocular hypertension, 
primary open-angle, pseudoexfoliation  glaucoma were enrolled. Following baseline 
measurements (office hours phasing) , fixed combination of brinzolamide 1%  and 
brimonidine  0.2%    was applied topically twice daily  for 4 weeks. Patients were 
examined at 4  weeks for IOP recordings  and  evaluation of side effects.s. The diurnal 
variation of IOP post- treatment  at 4 weeks was also seen. 
 
Results: Twenty five enrolled patients completed the study.  At 4  weeks, the mean 
IOP reduction was 4.43± 3.13 mmHg.  with fixed combination of brinzolamide 1%  
and brimonidine  0.2% . There was  17.69% ( range 4.76 – 36.58 %) reduction in IOP 
which was statistically significant at all time points. Four patients showed ≤ 2 mmHg 
reduction post-treatment which is most likely due to  non- compliance rather thn non-
response to the fixed combination. 
During 24- hour IOP recording showed low nocturnal pressures  with minimal 
fluctuations  at night but  an early morning peak (8am)Most patients had IOP 
fluctuation between 1-4mmHg.indicating  good overall control of IOP through the day 
and night. IOP variation of >4mmHg was seen in only 5 patients .  
 The most common side effect were ocular surface symptoms-  4 patients with burning 
sensation (16%),  8  patients with  foreign body sensation (32 %), 5 patients with 
watering (20%), 2 patients with hyperaemia (8%) . None of them require 
discontinuation of treatment due to side effects. The symptoms also tended to be better 
at 4 weeks compared to 2 weeks indicating a trend to better tolerability long term. 
There were no systemic adverse effects observed or reported by any patients  . 
 
Conclusion: In this short-term study, the  fixed combination of brinzolamide 1%  and 
brimonidine  0.2%   achieved mean reduction of  4.43± 3.13 mm Hg ; 17.69% ( range 
4.76 – 36.58 %)  at 1 month in our patients with primary open angle glaucoma and 
ocular hypertension .  
The amount of  IOP  reduction was statistically significant but  lower compared to that 
reported in other studies reported in Caucasian eyes. 
The  24 hour IOP recordings in patients on treatment of this drug showed low 
nocturnal IOPs  with minimal nocturnal fluctuation but an early morning peak (8am).  
Mild ocular surface symptoms  were the most common side effects which did not 
interfere with activities of daily life. No systemic adverse effects were seen in any of 
the patients.  None needed discontinuation of the drug.  
 
